Carla Liria Sánchez-Lafuente

Chronic and autoimmune diseases continue to rise across Canada, demonstrating the need for sustainable dietary strategies that promote long‐term health. Fermented foods (FFs) have emerged as a potential approach, yet national data on consumption patterns and public perceptions remain largely unknown. A cross‐sectional survey of 4045 Canadian adults was conducted (September–November 2023) to assess consumption patterns, including behaviors, perceptions, and general knowledge about FFs and fermentation practices. Overall, 25.7% of participants reported consuming all 18 surveyed FFs at least once. Cheese (95.7%) and yogurt (93.2%) were the most consumed, while fermented fish (38.9%) and fermented cereals/grains (40.2%) were least consumed. Consumption patterns varied by age, sex, income, and education. Lower intake was seen in older adults, those with lower income and education, and those for whom health was not a primary consideration in food choice. Taste was the main motivator for consumption, with health second. Home fermentation was uncommon (9.0%) but more frequent among younger, more educated individuals. While there was a willingness to try new products (29.1%) and engage in home fermentation (30.0%), participants expressed uncertainty about FF safety (18.4%) and potential health benefits (52.7%). Nonetheless, two‐thirds wanted to learn more about FFs, and nearly half preferred guidance from trusted sources such as Canada's Food Guide. This study is the first comprehensive assessment of FF consumption patterns and perceptions across Canada, revealing sociodemographic trends, knowledge gaps, and opportunities to strengthen consumer education, evidence‐based resources, and future public health initiatives related to FFs.

Stress and associated dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis is central to major depression etiology, as HPA axis hyperactivity and hypercortisolism are common occurrences in individuals with depression. Reelin, an extracellular matrix glycoprotein that plays numerous roles in brain development and function, is downregulated in several neuropsychiatric disorders. Reelin and its receptors are present throughout the HPA axis, and research has found that reelin levels are decreased in animal models of chronic stress in the hypothalamus. There may therefore be roles for reelin in regulating aspects of healthy HPA axis function and for reelin supplementation in restoring various facets of HPA axis function in chronic stress conditions, particularly those associated with HPA axis inhibition and stimulation. This review aims to summarize proposed roles for reelin in HPA axis activity, with a focus on the direct and indirect roles of reelin in restoring HPA axis homeostasis in chronic stress and depression. This review will explore possible interactions between reelin and the HPA axis in chronic stress conditions in order to expand our understanding of the mechanisms underlying the neurobiology of depression.

Current pharmacological treatments for depression fail to produce adequate remission in a significant proportion of patients. Increasingly, other systems, such as the microbiome–gut–brain axis, are being looked at as putative novel avenues for depression treatment. Dysbiosis and dysregulation along this axis are highly comorbid with the severity of depression symptoms. The endogenous extracellular matrix protein reelin is present in all intestinal layers as well as in myenteric and submucosal ganglia, and its receptors are also present in the gut. Reelin secretion from subepithelial myofibroblasts regulates cellular migration along the crypt–villus axis in the small intestine and colon. Reelin brain expression is downregulated in mood and psychotic disorders, and reelin injections have fast antidepressant-like effects in animal models of depression. This review seeks to discuss the roles of reelin in the gastrointestinal system and propose a putative role for reelin actions in the microbiota–gut–brain axis in the pathogenesis and treatment of depression, primarily reflecting on alterations in gut epithelial cell renewal and in the clustering of serotonin transporters.

A healthy diet has been highly associated with a decreased risk for mental health problems such as major depression. Evidence from human studies shows that diet can influence mood but there is a poor understanding of the molecular mechanisms behind these effects, especially the role of epigenetic alterations in the brain. Our objective was to use the Preferred Reporting Items for Systematic Reviews and Meta-Analysis extension for Scoping Reviews (PRISMA-ScR) format to gather all recent studies using animal models that investigate direct or indirect (on the offspring) effects of diet on depressive symptoms, including studies that assess epigenetic mechanisms in the brain. In this format, two authors conducted independent database searches of PubMed, Web of Science, and Academic search premier using one search block “diet epigenetics depression” to find papers published between 2000 and 2022. Relevant studies were selected using pre-defined inclusion/exclusion criteria that were performed independently by the two authors before a subset of studies were selected for qualitative analysis. A total of 11 studies met the inclusion criteria for this systematic scoping review. We found that the literature focuses primarily on the effects of individual nutrients, instead of a specific diet, on despair-like behaviour and anxiety. Studies are heterogenous with the techniques used to asses epigenetic changes in the brain and therefore making it hard to reach common mechanistic explanations. However, all studies report diet-induced changes in the epigenome mainly by the action of DNA methylation, histone acetylation and microRNAs that are parallelel with changes in behaviour. Moreover studies show that inadequate maternal diets can make the offspring more susceptible to develop anxiety and depressive-like behaviour later in life, which is paralleled with changes in the epigenome. Overall, this systematic review shows that there is some literature suggesting a role of brain epigenetics on the diet-induced protective or detrimental effects, specifically on anxiety and depressive-like behaviour. However, studies are limited, lacking the study of some types of diets, behavioural tasks or epigenetic mechanisms. Nevertherless, it shows the importance of genome-environment interactions, bringing new insights towards mechanisms that could be involved in the pathophysiology of mood disorders as well as putative therapeutic targets.

Methyl-CpG-binding protein 2 (MeCP2) is a transcriptional regulator that is highly abundant in the brain. It binds to methylated genomic DNA to regulate a range of physiological functions implicated in neuronal development and adult synaptic plasticity. MeCP2 has mainly been studied for its role in neurodevelopmental disorders, but alterations in MeCP2 are also present in stress-related disorders such as major depression. Impairments in both stress regulation and synaptic plasticity are associated with depression, but the specific mechanisms underlying these changes have not been identified. Here, we review the interplay between stress, synaptic plasticity, and MeCP2. We focus our attention on the transcriptional regulation of important neuronal plasticity genes such as BDNF and reelin (RELN). Moreover, we provide evidence from recent studies showing a link between chronic stress-induced depressive symptoms and dysregulation of MeCP2 expression, underscoring the role of this protein in stress-related pathology. We conclude that MeCP2 is a promising target for the development of novel, more efficacious therapeutics for the treatment of stress-related disorders such as depression.

Wound infection is a major clinical challenge that can significantly delay the healing process, can create pain, and requires prolonged hospital stays. Pre-clinical research to evaluate new drugs normally involves animals. However, ethical concerns, cost, and the challenges associated with interspecies variation remain major obstacles. Tissue engineering enables the development of in vitro human skin models for drug testing. However, existing engineered skin models are representative of healthy human skin and its normal functions. This paper presents a functional infected epidermis model that consists of a multilayer epidermis structure formed at an air-liquid interface on a hydrogel matrix and a three-dimensionally (3D) printed vascular-like network. The function of the engineered epidermis is evaluated by the expression of the terminal differentiation marker, filaggrin, and the barrier function of the epidermis model using the electrical resistance and permeability across the epidermal layer. The results showed that the multilayer structure enhances the electrical resistance by 40% and decreased the drug permeation by 16.9% in the epidermis model compared to the monolayer cell culture on gelatin. We infect the model with Escherichia coli to study the inflammatory response of keratinocytes by measuring the expression level of pro-inflammatory cytokines (interleukin 1 beta and tumor necrosis factor alpha). After 24 h of exposure to Escherichia coli, the level of IL-1β and TNF-α in control samples were 125 ± 78 and 920 ± 187 pg/mL respectively, while in infected samples, they were 1429 ± 101 and 2155.5 ± 279 pg/mL respectively. However, in ciprofloxacin-treated samples the levels of IL-1β and TNF-α without significant difference with respect to the control reached to 246 ± 87 and 1141.5 ± 97 pg/mL respectively. The robust fabrication procedure and functionality of this model suggest that the model has great potential for modeling wound infections and drug testing.